Hot Sale High Purity Anticoagulants Platelet Glycoprotein B Eptifibatide Powder CAS: 188627-80-7
China Hot Sale High Purity Anticoagulants Platelet Glycoprotein B Eptifibatide Powder CAS: 188627-80-7, Find details about China Eptifibatide, 188627-80-7 from Hot Sale High Purity Anticoagulants Platelet Glycoprotein B Eptifibatide Powder CAS: 188627-80-7
Basic Info.
Model NO.
188627-80-7
Trademark
Wuhan Wujia
Specification
1gram 10gram 1kg
Origin
Wuhan China
HS Code
2935900090
Model NO.
188627-80-7
Trademark
Wuhan Wujia
Specification
1gram 10gram 1kg
Origin
Wuhan China
HS Code
2935900090
Product Desciption
Hot Sale High Purity Anticoagulants Platelet Glycoprotein B Eptifibatide Powder CAS: 188627-80-7
Detailed Product Information
Product Name : Eptifibatide
Trade Name: integrilin
CAS No.:188627-80-7
Molecular Formula: C35H49N11O9S2
Molecular Weight:831.96g/mol
Purity : 98% HPLC
Appearance: Lyophilized Powder
Typical use:Anticoagulants
Shelf Life :2 years
Payment Terms:T/T, Western Union, Money Gram
Storage:Refrigeration keep dry and away from light.
Description:
Eptifibatide is a platelet glycoprotein b/a receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur . It has Strong effect and high selectivity . It has no antigenicity,and it does not cause allergic reactions. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events. It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance.
Application:
Etibatide is a glycoprotein (GP) IIb/IIIa receptor (platelet factor I receptor) antagonist. By selectively and reversibly inhibiting the final common pathway of platelet aggregation (plasma coagulation factor I binds to GPIIb/IIIa), the ischemic state due to thrombosis can be reversed.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodi should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
Detailed Product Information
Product Name : Eptifibatide
Trade Name: integrilin
CAS No.:188627-80-7
Molecular Formula: C35H49N11O9S2
Molecular Weight:831.96g/mol
Purity : 98% HPLC
Appearance: Lyophilized Powder
Typical use:Anticoagulants
Shelf Life :2 years
Payment Terms:T/T, Western Union, Money Gram
Storage:Refrigeration keep dry and away from light.
Description:
Eptifibatide is a platelet glycoprotein b/a receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur . It has Strong effect and high selectivity . It has no antigenicity,and it does not cause allergic reactions. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events. It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance.
Application:
Etibatide is a glycoprotein (GP) IIb/IIIa receptor (platelet factor I receptor) antagonist. By selectively and reversibly inhibiting the final common pathway of platelet aggregation (plasma coagulation factor I binds to GPIIb/IIIa), the ischemic state due to thrombosis can be reversed.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodi should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
You Might Also Like
Triac 0-10V Dali Dimmable Recessed LED Downlight/ COB LED Ce......
GMP Factory Supply Food Grade Phycocyanin Spirulina Extract
Table Tennis Racket with Rubber + Bag Ping Pong Bat
3mh Cool Giant Fat Inflatable Cat Cartoon for Advertising
Mslfp14 17*17 Wired Box Size X-ray Digital Flat Panel Detect......
Portable Glass Shape Edge Polishing Machine
A4 A3 Paper Wrapping Machine
Stainless Steel Angle Tube Strainer
Sinchold 9220/20/45 Forged Steel Welded Crane Rail Clips
Warehouse Tent Made by Superb Tent
Thyristor Rectified CO2 MIG Mag Arc Welding Machine